同源盒蛋白纳米
食管癌
癌症干细胞
癌症研究
癌症
医学
干细胞
癌细胞
肿瘤科
内科学
生物
胚胎干细胞
诱导多能干细胞
细胞生物学
生物化学
基因
作者
Toru Narusaka,Toshiaki Ohara,Kazuhiro Noma,Noriyuki Nishiwaki,Yoshiteru Katsura,Takuya Kato,Hiroaki Sato,Yasuko Tomono,Shinichi Kikuchi,Hiroshi Tazawa,Yasuhiro Shirakawa,Akihiro Matsukawa,Toshiyoshi Fujiwara
摘要
Abstract Esophageal cancer is a disease showing poor prognosis. Although combination chemotherapy using cisplatin (CDDP) and 5‐fluorouracil is standard for unresectable esophageal cancer, the response rate is 35%. Cancer stem cells (CSCs) and inflammation are reportedly responsible for the poor prognosis of esophageal cancer. However, comprehensive analyses have not been conducted and proposals for progress remain lacking. Iron is known to be a key factor in the stemness of CSCs. Our study focused on the therapeutic potential of iron control using iron chelators for CSCs in esophageal cancer. Among 134 immunohistochemically analyzed cases, Nanog expression was high in 98 cases and low in 36 cases. High Nanog expression correlated with low overall and disease‐free survivals. The iron chelators deferasirox (DFX) and SP10 suppressed the proliferation and expression of stemness markers in TE8 and OE33 cells. DFX and SP10 did not induce compensatory interleukin (IL)‐6 secretion, although CDDP did result in high induction. Moreover, BBI608 and SSZ, as other CSC‐targeting drugs, could not suppress the expression of stemness markers. Overall, Nanog expression appears related to poor prognosis in esophageal cancer patients, and inhibition of stemness and compensatory IL‐6 secretion by iron chelators may offer a novel therapeutic strategy for esophageal cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI